| Bioactivity | Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells)[1][2]. |
| Invitro | Epiyangambin (0-25 µM; 24 h) 以剂量依赖性方式抑制 SW480 细胞的生长[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | Epiyangambin (20 mg/kg) 显著抑制血小板激活因子受体 (PAF) 诱导的大鼠血小板减少症[2]。 |
| Name | Epiyangambin |
| CAS | 24192-64-1 |
| Formula | C24H30O8 |
| Molar Mass | 446.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hausott B, et al. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 2003 Oct;129(10):569-76. [2]. Castro-Faria-Neto HC, et al. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. J Lipid Mediat. 1993 May;7(1):1-9. |
Epiyangambin
CAS: 24192-64-1 F: C24H30O8 W: 446.49
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.